2020 Volume 44 Issue 1 Pages 15-22
The effects of xanthine oxidase inhibitor, febuxostat, for urine urate excretion are still unclear. This study is conducted to clarify the effects of febuxostat for urine urate excretion. This is a prospective observation study (UMIN: 7350). We enrolled 16 hyperuricemic men over 20 years old whose serum uric acid levels were 8.0 mg/dL and more. The study subjects started 10 mg/day of febuxostat for two weeks, and then, the dosage was increased the dosage of 20 mg after 2weeks. They continued 20 mg/day of febuxostat for 10 weeks. We assessed the amount of urine urate excretion as (urine urate / urine creatinine), and urine urate excretion rate as ((urine urate / urine creatinine) / (serum urate / serum creatinine)) by Wilcoxon analysis. The results showed that 13 subjects were classified as low urate excretion type based on FEUA at the entry. After febuxostat treatments, FEUA decreased in 12 subjects and the amount of urine urate excretion decreased in 15 subjects. These results showed that xanthine oxidase inhibitor directly changed the urine urate excretion. We should consider the change of hyperuricemia categorization after urate lowering medication.
